Results 11 to 20 of about 7,511 (210)

The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. [PDF]

Adv Drug Deliv Rev, 2015
Immunoglobulin G (IgG)-based drugs are arguably the most successful class of protein therapeutics due in part to their remarkably long blood circulation. This arises from IgG interaction with the neonatal Fc receptor, FcRn. FcRn is the central regulator of IgG and albumin homeostasis throughout life and is increasingly being recognized as an important ...
Sockolosky JT, Szoka FC.
europepmc   +7 more sources

Targeting the neonatal Fc receptor (FcRn) is not beneficial in an animal model of chronic neuritis. [PDF]

Immunol Res
AbstractThe inhibition of the neonatal Fc receptor (FcRn) is a promising therapeutic pathway in certain autoimmune disorders to reduce the amount of circulating pathogenic IgG autoantibodies by interfering with their recycling system. FcRn antibodies are currently being tested in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Mausberg AK, Szepanowski F, Eggert B, Liebig KC, Kleinschnitz C, Kieseier BC, Stettner M.   +6 more
europepmc   +4 more sources

Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice. [PDF]

MAbs, 2016
The neonatal Fc receptor (FcRn) is a homeostatic receptor responsible for prolonging immunoglobulin G (IgG) half-life by protecting it from lysosomal degradation and recycling it to systemic circulation. Tissue-specific FcRn expression is a critical parameter in physiologically-based pharmacokinetic (PBPK) modeling for translational pharmacokinetics of
Fan YY, Avery LB, Wang M, O'Hara DM, Leung S, Neubert H.   +5 more
europepmc   +6 more sources

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. [PDF]

MAbs, 2015
The neonatal Fc receptor (FcRn) is expressed by cells of epithelial, endothelial and myeloid lineages and performs multiple roles in adaptive immunity. Characterizing the FcRn/IgG interaction is fundamental to designing therapeutic antibodies because IgGs with moderately increased binding affinities for FcRn exhibit superior serum half-lives and ...
Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A.   +11 more
europepmc   +6 more sources

Neonatal Fc receptor (FcRn) and maternal-to-newborn IgE absorption. [PDF]

Clin Exp Allergy, 2012
From 1949-1966, a series of experimental studies by Professor F. W. Rogers Brambell (1901-1970; memoirs (1)) revealed the transmission of immunoglobulin from the mother to the fetus and newborn (2-4). In 1966, he published a review article in The Lancet describing that the selective transmission of γ-globulin from the mother to the offspring could ...
Hogan SP.
europepmc   +7 more sources

Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. [PDF]

J Biol Chem, 2014
A major challenge for the therapeutic use of many peptides and proteins is their short circulatory half-life. Albumin has an extended serum half-life of 3 weeks because of its size and FcRn-mediated recycling that prevents intracellular degradation, properties shared with IgG antibodies.
Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, Allan E, Evans L, Bjørås M, Kjærulff S, Sleep D, Sandlie I, Cameron J.   +16 more
europepmc   +9 more sources

Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion Technology. [PDF]

Eur J Immunol
We engineered the IgG‐degrading enzyme IdeS as a Fc‐fusion protein. IdeS‐Fc exhibits similar hydrolysing efficacy to its native counterpart, but has an increased half‐life, translating into prolonged therapeutic degradation of IgG. ABSTRACT Imlifidase (IdeS) is a bacterial protease that hydrolyzes human IgG in their hinge region, decreasing their half ...
Daventure V, Bou-Jaoudeh M, Hannachi E, Reyes-Ruiz A, Trecco A, Delignat S, Lacroix-Desmazes S, Deligne C.   +7 more
europepmc   +2 more sources

Individualized Dosing of Efgartigimod in Patients With Generalized Myasthenia Gravis: Clinical Experience at a Single Center. [PDF]

Muscle Nerve
ABSTRACT Introduction/Aims Neonatal Fc receptor (FcRn) inhibitors represent a promising treatment option for patients with generalized myasthenia gravis (gMG); however, data on clinical use are limited. The aim of this report is to describe one center's approach to efgartigimod dosing in patients with gMG.
Silvestri NJ.
europepmc   +2 more sources

Targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases and maternal-fetal immune cytopenias. [PDF]

Transfusion, 2021
Wyckoff SL, Hudson KE.
europepmc   +3 more sources

Podocyte-specific knockout of the neonatal Fc receptor (FcRn) results in differential protection depending on the model of glomerulonephritis. [PDF]

PLoS One, 2020
Dylewski JF, Tonsawan P, Garcia G, Lewis L, Blaine J.   +4 more
europepmc   +3 more sources